1. Introduction
Antibody-drug conjugates (ADC) are composed of three main components: the antibody, the drug (often referred to as the payload or a small-molecule toxin), and the linker. ADCs work by using the antibody's specific affinity for a target antigen to deliver the conjugate to the target site. Upon binding to the antigen, the ADC is internalized by the target cell, where the payload is then released to exert its cytotoxic effects, eliminating the targeted cell.
DMPK for an ADC is therefore not one question. The conjugate, the linker, and the released payload each have their own distribution, stability, and clearance behavior. Most regulatory packages need all three described separately.
Prisys Biotech specializes in preclinical pharmacology research with Cynomolgus macaques, offering large-animal studies that provide critical insights into drug behavior and efficacy. Expertise in ADC pharmacokinetics (PK) and pharmacodynamics (PD) supports precise assessment of drug distribution, metabolism, and elimination. Total antibody, conjugated antibody, and free payload are quantified separately, so exposure and effect can be read against one dosing schedule.
Since ADC drugs differ from monoclonal antibodies (mAbs) and are generally administered intravenously (IV), this document does not discuss absorption characteristics and instead focuses on the distribution and elimination of ADCs.
2. Distribution of ADC Drugs
As ADCs primarily consist of an antibody structure, their distribution characteristics largely resemble those of naked antibodies. Three main factors influence ADC distribution: target-mediated specific distribution, convective fluid flow between plasma, tissue fluid, and lymph, and the intrinsic properties of the ADC itself.
Target-Mediated Distribution: This process is mainly influenced by the expression of target antigens and the rate of endocytosis. Ideally, the target antigen expression should significantly differ between tumor and normal tissues to enhance therapeutic efficacy and minimize toxicity.
Convective Fluid Flow: Due to their large molecular weight (~150 kDa), ADCs remain in the vasculature shortly after administration, reaching a steady-state volume of distribution (Vss) around 0.2 L/kg.
Intrinsic Properties of the ADC: Molecular size, charge, and hydrophobicity all impact the ADC's ability to traverse capillary pores. High DAR (drug-to-antibody ratio) values, typically above 4, may increase plasma clearance rates and hepatic distribution.
Plasma concentrations describe the vascular compartment, not the target tissue. Where payload retention differs between tumor and normal tissue, tissue-level measurement is needed to check what the plasma curve implies, and Prisys runs Biodistribution Imaging Service work alongside plasma sampling for that purpose.
3. Elimination of ADC Drugs
ADC elimination is complex, given its structural composition of antibody, linker, and payload. Key mechanisms include:
3.1 Target-Mediated Elimination: Following binding with membrane surface antigens, ADCs undergo receptor-mediated endocytosis and lysosomal degradation. Higher endocytic rates facilitate drug efficacy by enabling ADC internalization and payload release.
3.2 FcRn Receptor Interaction: The FcRn receptor protects the ADC from degradation within cells, extending plasma half-life and potentially enhancing ADC-mediated antibody-dependent cellular cytotoxicity (ADCC) effects.
3.3 Linker Stability: Linkers are classified as cleavable or non-cleavable, impacting payload release mechanisms and influencing both efficacy and toxicity. Cleavable linkers rely on pH differences or specific enzymes, while non-cleavable linkers release payloads only upon antibody breakdown.
3.4 Payload Dynamics: Once released, payloads may either diffuse freely or remain localized. Payloads that are substrates of efflux transporters, such as P-glycoprotein, may require modifications to increase retention within target cells.
Which route dominates depends on the construct. A stable linker with a payload that is a poor efflux substrate may clear almost entirely through the antibody route, while a cleavable linker with a membrane-permeable payload loses material to redistribution and efflux. The ADME package for an ADC therefore rarely reduces to a single half-life.
4. Conclusion
This article has outlined the ADME mechanisms and influencing factors for ADC drugs. Because ADC drugs are relatively new compared with small-molecule drugs, several of these mechanisms are still being characterized, and assumptions carried over from mAb programs do not always hold.
Prisys Biotech runs PK and PD studies in non-human primates through its NHP Pharmacology platform, with the imaging, bioanalytical, and pathology readouts that ADC programs tend to need. If you are planning a study, the team can discuss design options for your construct.
